Clinical Trials List
2025-02-01 - 2033-12-31
Phase II
Recruiting3
ICD-10C50.911
Malignant neoplasm of unspecified site of right female breast
ICD-10C50.912
Malignant neoplasm of unspecified site of left female breast
ICD-10C50.919
Malignant neoplasm of unspecified site of unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.9
Malignant neoplasm of female breast, unspecified
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/01
Investigators and Locations
Co-Principal Investigator
- 黃怡菁 Division of Hematology & Oncology
- Zhu-Jun Loh Division of General Surgery
- Chun-Hui Lee Division of Hematology & Oncology
- 楊舜如 Division of Hematology & Oncology
- 黃怡璇 Division of Hematology & Oncology
- Jui-Hung Tsai Division of Hematology & Oncology
- Shang-Hung Chen Division of Hematology & Oncology
- Wei-Pang Chung Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Wen-Chi Shen Division of Hematology & Oncology
- Wen-Ling Kuo Division of General Surgery
- Chan-Keng Yang Division of Hematology & Oncology
- 阮昱翔 Division of Radiology
- Li-Yu Lee Division of Others -
- 周旭桓 Division of General Surgery
- Mengting Peng Division of Hematology & Oncology
- 沈士哲 Division of General Surgery
- Yung-Chang Lin Division of Hematology & Oncology
- Chi-Chang Yu Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
12 participants
-
Global
100 participants
